中低收入国家麻疹免疫接种持续存在差距:基于2024年WHO/UNICEF国家免疫覆盖率估算修订版的分析
该研究利用2024年WHO/UNICEF国家免疫覆盖率估算修订版数据,分析2019至2024年137个中低收入国家的麻疹含疫苗第一剂和第二剂覆盖率趋势、不公平性及优先人群。结果显示2024年平均MCV1覆盖率为79.2%,脆弱国家显著低于非脆弱国家,差距持续扩大,且不平等程度上升。研究通过聚类识别出四种覆盖率特征类型,为公平导向的资金和策略提供框架。
要点
- 2024年中低收入国家平均MCV1覆盖率为79.2%,低于95%目标阈值。
- 脆弱国家MCV1覆盖率68.5%,比非脆弱国家低18.1个百分点。
- 2019至2024年覆盖率不平等基尼系数从0.22升至0.25。
核心结论
- 中低收入国家麻疹免疫接种差距持续存在且不断扩大,尤其在脆弱环境中,威胁IA2030的90%覆盖率目标。
- 结合脆弱性敏感聚类和有界预测,可提供一个实用框架,用于在最需要的地方优先安排公平导向的资金和操作策略。
研究设计与样本
- 基于2019至2024年137个中低收入国家的WUENIC 2024修订版数据进行分析。
- 使用描述性统计、Welch t检验和Wilcoxon秩和检验比较脆弱与非脆弱国家,计算基尼系数评估不平等,对覆盖率、MCV1至MCV2脱落、变化、未接种数和脆弱性进行k均值聚类(k=4),并用有界线性模型预测MCV1至2030年。
主要发现
- 2024年平均MCV1覆盖率为79.2%(95%CI:76.8-81.6),低于95%阈值;脆弱中低收入国家为68.5%,非脆弱国家为87.4%(差异-18.1个百分点;p<0.001)。
- MCV2差距更大(-26.9个百分点;p<0.001)。
- 2019至2024年不平等上升(基尼系数0.22→0.25)。
- 预测显示2030年MCV1覆盖率为84.2%,脆弱中低收入国家偏离轨道。
关键数值与推荐
- 2024年平均MCV1覆盖率79.2%(95%CI:76.8-81.6),脆弱国家68.5%,非脆弱国家87.4%,差异-18.1个百分点(p<0.001)。
- MCV2差距-26.9个百分点(p<0.001)。
- 基尼系数从2019年0.22升至2024年0.25。
- 聚类k=4,各类型国家数分别为22、44、31、40。
临床怎么用
- 利用脆弱性敏感聚类识别国家类型,针对极低覆盖率、高脱落、高脆弱性国家采用冲突适应性补充免疫活动。
- 对高覆盖率、低脱落国家重点维持成果;对低覆盖率、严重脱落国家开展后续 campaign;对低覆盖率、中度脱落国家扩大第一剂可及性。
- 将公平导向资金优先投向麻疹免疫差距最大和脆弱性最高的地区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Measles remains a leading vaccine-preventable killer in low- and middle-income countries (LMICs). Using the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) 2024 revisions, this article assesses measles-containing vaccine first-dose (MCV1) and second-dose (MCV2) coverage trends, inequities, and priority groups for targeted action. METHODS: Data from 2019 to 2024 for 137 LMICs were analysed using descriptive statistics; Welch's t-tests and Wilcoxon rank-sum tests to compare fragile versus non-fragile states; Gini coefficients for inequality; k-means clustering (k = 4) on coverage, MCV1-to-MCV2 dropout, change, unvaccinated counts, and fragility; and bounded linear models to project MCV1 to 2030. RESULTS: In 2024, mean MCV1 coverage was 79.2% (95% CI: 76.8-81.6)-below the 95% threshold-with fragile LMICs at 68.5% versus 87.4% in non-fragile LMICs (difference - 18.1 percentage points; p < 0.001). MCV2 gaps were larger (-26.9 percentage points; p < 0.001). DTP1-based zero-dose prevalence was 20.8%, with 15.6 million children unvaccinated for MCV1 and 22.4 million for MCV2; West and Central Africa accounted for 7.2 million MCV1-unvaccinated (46.2%). Inequality rose (Gini 0.22 → 0.25, 2019-2024). Projections indicate MCV1 of 84.2% by 2030, with fragile LMICs off-track. Clustering identified four profiles: (1) very low coverage, high dropout, high fragility (22 countries); (2) high coverage, low dropout (44); (3) low coverage, severe dropout (31); and (4) low coverage, moderate dropout (40), each implying distinct priorities (conflict-adapted SIAs; sustaining gains; follow-up campaigns; expanding first-dose access). CONCLUSIONS: Persistent and widening measles immunization gaps-especially in fragile settings-threaten IA2030's 90% coverage targets. Pairing the 2024 WUENIC revision with fragility-sensitive clustering and bounded projections provides a practical framework to prioritize equity-focused funding and operational strategies where need is greatest.
引用
- Mwale M. Persistent measles immunization gaps in LMICs: Insights from the 2024 revision of the WHO/UNICEF estimates of National Immunization Coverage. Vaccine. 2026. PMID: 41621116. doi:10.1016/j.vaccine.2026.128298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。